392 related articles for article (PubMed ID: 29069085)
1. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.
Wood SF; Podrasky J; McMonagle MA; Raveendran J; Bysshe T; Hogenmiller A; Fugh-Berman A
PLoS One; 2017; 12(10):e0186060. PubMed ID: 29069085
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
3. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study.
Goel V; Moran B; Kaizer AM; Sivanesan E; Patwardhan AM; Ibrahim M; DeWeerth JC; Shannon C; Shankar H
Anesth Analg; 2021 Jun; 132(6):1748-1755. PubMed ID: 33591120
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
5. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US.
Nguyen AM; Anderson KE; Anderson G; Johnson TV
JAMA Ophthalmol; 2022 Sep; 140(9):855-862. PubMed ID: 35900736
[TBL] [Abstract][Full Text] [Related]
6. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases.
Goupil B; Balusson F; Naudet F; Esvan M; Bastian B; Chapron A; Frouard P
BMJ; 2019 Nov; 367():l6015. PubMed ID: 31690553
[TBL] [Abstract][Full Text] [Related]
7. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.
Hartung DM; Johnston K; Cohen DM; Nguyen T; Deodhar A; Bourdette DN
JAMA Netw Open; 2018 Jun; 1(2):e180482. PubMed ID: 30646086
[TBL] [Abstract][Full Text] [Related]
8. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
[TBL] [Abstract][Full Text] [Related]
9. Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty.
Hollander MAG; Donohue JM; Stein BD; Krans EE; Jarlenski MP
J Gen Intern Med; 2020 Aug; 35(8):2451-2458. PubMed ID: 31792860
[TBL] [Abstract][Full Text] [Related]
10. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
11. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
12. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
13. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
14. Opioid prescription by gynecologic oncologists: An analysis of Medicare Part D claims.
Samuel D; Nevadunsky NS; Miller DT; Isani S; Kuo DYS; Gressel GM
Curr Probl Cancer; 2021 Apr; 45(2):100655. PubMed ID: 32994074
[TBL] [Abstract][Full Text] [Related]
15. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Affordable Care Act's Physician Payments Sunshine Act on branded statin prescribing.
Li J; Wu B; Flory J; Jung J
Health Serv Res; 2022 Oct; 57(5):1145-1153. PubMed ID: 35808991
[TBL] [Abstract][Full Text] [Related]
17. Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs.
Perlis RH; Perlis CS
PLoS One; 2016; 11(5):e0155474. PubMed ID: 27183221
[TBL] [Abstract][Full Text] [Related]
18. The impact of reducing pharmaceutical industry payments on physician prescribing.
Parker-Lue S
Health Econ; 2020 Mar; 29(3):382-390. PubMed ID: 31930636
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
20. Prescription patterns and costs of acne/rosacea medications in Medicare patients vary by prescriber specialty.
Zhang M; Silverberg JI; Kaffenberger BH
J Am Acad Dermatol; 2017 Sep; 77(3):448-455.e2. PubMed ID: 28651825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
